HC Wainwright Increases Earnings Estimates for Bausch + Lomb

Bausch + Lomb Corporation (NYSE:BLCO) – Stock analysts at HC Wainwright increased their Q4 2026 earnings per share (EPS) estimates for shares of Bausch + Lomb in a report issued on Monday, November 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.34 for the quarter, up from their prior forecast of $0.28. HC Wainwright has a “Neutral” rating and a $22.00 price target on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.94 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q3 2027 earnings at $0.25 EPS, Q4 2027 earnings at $0.35 EPS and FY2027 earnings at $1.05 EPS.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.13. The firm had revenue of $1.38 billion for the quarter, compared to analysts’ expectations of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.18 earnings per share.

Other research analysts have also recently issued research reports about the company. Citigroup boosted their price target on Bausch + Lomb from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. JPMorgan Chase & Co. lifted their price objective on Bausch + Lomb from $16.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 29th. Barclays upgraded Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a report on Tuesday, September 15th. Finally, Royal Bank Of Canada increased their target price on Bausch + Lomb from $21.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Bausch + Lomb has a consensus rating of “Hold” and a consensus target price of $20.83.

Bausch + Lomb Stock Performance

Shares of NYSE BLCO opened at $20.01 on Wednesday. Bausch + Lomb has a 52-week low of $14.44 and a 52-week high of $21.36. The company has a market cap of $7.15 billion, a PE ratio of -64.55, a P/E/G ratio of 0.53 and a beta of 0.52. The firm’s 50 day moving average price is $17.46 and its 200-day moving average price is $16.71. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.04 and a current ratio of 1.56.

Insider Activity at Bausch + Lomb

In other news, Director Eschenbach Andrew C. Von sold 12,500 shares of Bausch + Lomb stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the transaction, the director owned 69,792 shares in the company, valued at $1,151,568. This trade represents a 15.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $20.48, for a total value of $2,294,067.20. Following the transaction, the chief accounting officer owned 45,831 shares in the company, valued at $938,618.88. This trade represents a 70.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 183,474 shares of company stock worth $3,488,437 over the last quarter. Insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

Large investors have recently made changes to their positions in the business. State of Wyoming boosted its position in shares of Bausch + Lomb by 6.9% during the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock worth $234,000 after acquiring an additional 887 shares during the last quarter. Beach Point Capital Management LP purchased a new stake in shares of Bausch + Lomb during the 3rd quarter valued at about $5,882,000. Counterpoint Mutual Funds LLC purchased a new stake in shares of Bausch + Lomb during the 3rd quarter valued at about $670,000. Roxbury Financial LLC bought a new position in shares of Bausch + Lomb in the 3rd quarter valued at about $33,000. Finally, Engineers Gate Manager LP purchased a new position in Bausch + Lomb in the second quarter worth about $1,479,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb News Summary

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Analyst earnings estimates increased: HC Wainwright raised its forecasts for Q4 2026 EPS to $0.34 from $0.28 and FY2027 EPS to $1.05 from $0.89. It also lifted estimates for Q3 and Q4 2027. Higher projections suggest improving expectations for future earnings.
• Neutral Sentiment: Rating remains cautious: Despite the estimate increases, HC Wainwright kept its Neutral rating and $22 price target after recently downgrading BLCO from Buy. The target is above the $20.01 reference price, but the rating signals limited conviction in outperformance. Bausch + Lomb Stock Rating Lowered by HC Wainwright
• Negative Sentiment: Significant insider sale: Chief Accounting Officer Frederick Munsch sold 112,015 shares for about $2.29 million, cutting his reported holdings by roughly 71%. The sale could weigh on sentiment, although insider transactions do not necessarily indicate a negative outlook. Bausch + Lomb CAO Sells Shares

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.